From the laboratory perspective, effective management of patients with chronic myeloid
leukemia (CML) requires accurate diagnosis, assessment of prognostic markers, sequential …

There are different BCR-ABL1 fusion genes that are translated into proteins that are different
from each other, yet all leukemogenic, causing chronic myeloid leukemia (CML) or acute …

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
(Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] …

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
resulting from a reciprocal translocation between chromosomes 9 and 22 [t9; 22] that gives …

With treatment-free remission (TFR) rapidly becoming the ultimate goal of therapy in chronic
myeloid leukemia (CML), there is a need to develop strategies to maximize sustained TFR …

Background Stopping tyrosine kinase inhibitor (TKI) treatment has become a realistic and
safe objective for patients who have chronic myeloid leukemia (CML). Both a sustained …

Chronic myeloid leukemia is driven by a hybrid gene, BCR-ABL1, that codes for a
leukemogenic tyrosine kinase (TK) protein of 210 KDa (p210 BCR-ABL1). Resistance to TK …

June 2018 was the 20th anniversary of the clinical use of the first tyrosine kinase inhibitor
(TKI), imatinib, for chronic myeloid leukemia. Since then, the change in prognosis for …

Chronic myeloid leukemia is characterized by a single genetic abnormality resulting in a
fusion gene whose mRNA product is easily detected and quantified by reverse-transcriptase …

Abstract Purpose of Review Clinical factors alone do not enable us to differentiate which
patients will maintain treatment-free remission (TFR) from those who are likely to relapse …